Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsCash from RestructuringChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyra Therapeutics (LYRA) Change in Account Payables (2021 - 2025)

Lyra Therapeutics (LYRA) has disclosed Change in Account Payables for 5 consecutive years, with -$120000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Change in Account Payables rose 95.37% to -$120000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was -$1.7 million, a 59.81% increase, with the full-year FY2024 number at -$1.9 million, down 519.33% from a year prior.
  • Change in Account Payables was -$120000.0 for Q3 2025 at Lyra Therapeutics, down from -$45000.0 in the prior quarter.
  • In the past five years, Change in Account Payables ranged from a high of $3.3 million in Q1 2023 to a low of -$3.5 million in Q4 2023.
  • A 5-year average of -$111421.1 and a median of -$106000.0 in 2023 define the central range for Change in Account Payables.
  • Peak YoY movement for Change in Account Payables: tumbled 435.4% in 2022, then skyrocketed 2343.4% in 2024.
  • Lyra Therapeutics' Change in Account Payables stood at $1.2 million in 2021, then plummeted by 289.69% to -$2.2 million in 2022, then plummeted by 57.53% to -$3.5 million in 2023, then surged by 68.51% to -$1.1 million in 2024, then soared by 89.22% to -$120000.0 in 2025.
  • Per Business Quant, the three most recent readings for LYRA's Change in Account Payables are -$120000.0 (Q3 2025), -$45000.0 (Q2 2025), and -$454000.0 (Q1 2025).